International Journal of Endocrinology / 2018 / Article / Tab 2

Research Article

A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients

Table 2

Characteristics and plasma biochemical parameters of T2D patients and healthy volunteers.

Healthy volunteersT2D patients value

Age (years)51 ± 763 ± 90.329
Duration of diabetes (years)19 ± 6
Body weight (kg)69 ± 374 ± 90.666
BMI (kg/m2)22.6 ± 0.826.4 ± 3.20.282
SBP (mmHg)117 ± 3113 ± 20.376
DBP (mmHg)76 ± 570 ± 30.284
Total-C (mg/dL)189 ± 6187 ± 100.84
LDL-C (mg/dL)120 ± 4119 ± 90.888
HDL-C (mg/dL)45 ± 639 ± 50.393
Triglyceride (mg/dL)118 ± 13149 ± 40.06
FBG (mg/dL)93 ± 2189 ± 24
HbA1c (%)5.4 ± 0.28.3 ± 0.2
Retinopathy (NDR/SDR/PPDR/PDR)NA2/0/0/2
Nephropathy (1/2/3/4/5)NA0/3/1/0/0
Macroangiopathy (CVD/CAD/PAD/CAD + PAD/none)NA0/0/0/2/2
Daily bolus insulin dose (unit)36 ± 9
Daily basal insulin dose (unit)12 ± 3
Total daily insulin dose (unit)48 ± 12
Use of OADs (Met/Met + Pio/none)0/0/41/1/20.264
Lipid-lowering drugs (statin/none)2/24/00.103
Antihypertensive drugs (ARB/ARB + β-blocker/none)0/0/42/1/10.091

T2D: type 2 diabetes; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; Total-C: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FBG: fasting blood glucose; HbA1c: hemoglobin A1c; NDR: no diabetic retinopathy; SDR: simple diabetic retinopathy; PPDR: preproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; NA: not available; —: none; CVD: cerebrovascular disease; CAD: coronary artery disease; PAD: peripheral artery disease; OADs: oral antidiabetic drugs; Met: metformin; Pio: pioglitazone; ARB: angiotensin II receptor blocker. Results are presented as mean values ± SEM and analyzed with unpaired -test. Categorical variables were compared by the chi-square test. vs. healthy volunteers.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.